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Adipose-derived stromal cellAlthough Toll-like receptors (TLRs) have been implicated in the regulation of stem cell functions, their role in os-
teogenic differentiation of adipose-derived stromal cells (ASCs) has not been reported. We found that ASCs ex-
press a restricted subset of TLRs, including TLR1–TLR5, and that TLR agonists such as Pam3CSK4 (TLR1/2 agonist),
polyinosinic:polycytidylic acid (TLR3 agonist), lipopolysaccharide (TLR4 agonist), and ﬂagellin (TLR5 agonist),
but not R848 (TLR7/8 agonist), consistently induced osteogenic differentiation in murine-derived ASCs, which
coincided with the TLR expression pattern of ASCs. Cytokine expression proﬁles induced by TLR agonists and re-
sults from subsequent functional assays indicated that interleukin-6 (IL-6) together with soluble IL-6 receptor
(sIL-6R) enhanced osteogenic differentiation of ASCs by activating STAT3. Small interfering RNA (siRNA)-
mediated STAT3-silencing blunted osteogenesis and the expression of osteogenic markers, whereas STAT3
overexpression resulted in an increase in osteogenesis. Consistently, STAT3 inhibitor treatment reduced osteogen-
esis, STAT3 phosphorylation, and expression of osteogenic markers including osterix. Chromatin immunoprecip-
itation (ChIP) assays indicated that STAT3 binding to the STAT3-binding sites on the osterix promoter increased
during IL-6-stimulated osteogenesis. Our results thus establish TLRs as novel regulators of ASCs which signal
through IL-6/STAT3 pathway and induce osterix expression as a part of the osteogenesis.
© 2013 Elsevier B.V. All rights reserved.1. Introduction
Toll-like receptors (TLRs) are a family of pattern recognition recep-
tors that sense pathogen-associated molecular patterns of microbial
pathogens [1]. Ten human and 12murine TLRs have been characterized
such as TLR1–TLR10 in humans, and TLR1–TLR9, TLR11, TLR12 and
TLR13 in mice. The murine TLR10 homolog is believed to be a
pseudogene. TLR2 is essential for the recognition of lipoproteins and
lipoteichoic acids in Gram-positive bacteria. TLR3 is implicated in
virus-derived double-stranded RNA. TLR4 is predominantly activated
by lipopolysaccharide (LPS). TLR5 detects bacterial ﬂagellin, and TLR9
is required for the response to unmethylated CpG DNA [2–5]. Finally,
TLR7 and TLR8 recognize small synthetic antiviral molecules [6], andolyinosinic:polycytidylic acid;
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l rights reserved.single-stranded RNA is their natural ligand [7]. Although TLRs have
been extensively studied in the early innate immune response to invad-
ing pathogens by sensing microorganisms [8,9], TLRs and their ligands
also regulate functions of mesenchymal stem cells (MSCs) [10,11]. Spe-
ciﬁcally, Pevsner-Fischer et al. [12] found that TLRs serve as regulators
of MSC proliferation and differentiation and might affect the mainte-
nance of MSC multipotency. However, the molecular mechanisms in-
volved in the differentiation of MSCs by TLR ligand stimulation remain
to be further investigated.
Interleukin-6 (IL-6) is a pleiotropic cytokine that regulates immune
responses, acute phase reactions, and hematopoiesis and may play a
central role in host defense mechanisms [13]. IL-6 is usually not pro-
duced constitutively by normal cells, but its expression is readily in-
duced by a variety of cytokines, LPS, or viral infections in a variety of
cells [14,15]. IL-6 binds to its membrane-bound receptor (IL-6R) or its
soluble receptor (sIL-6R). The complex of IL-6/IL-6R (or IL-6/sIL-6R) in-
teracts with the gp130 protein, which dimerizes and initiates down-
stream signaling [16]. Thus, either the membrane-bound or the
soluble IL-6R mediates the IL-6 signal in cells, as virtually all cells in
the body express gp130 [17]. IL-6 signaling triggers activation of the
gp130-associated Janus kinase pathway [18]. This leads to activation
of STAT3 by tyrosine phosphorylation and then to STAT3 dimerization
[19]. Dimerized STAT3 is subsequently translocated to the nucleus
where it binds to speciﬁc DNA sites as homo or heterodimers to stimu-
late transcription of response genes [20].
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tissues, including bone marrow, adipose tissue and muscle [21], and
differentiate into several lineages such as osteoblasts, chondrocytes,
or adipocytes [22]. In addition to the multilineage differentiation
capacity that is useful for tissue regeneration, MSCs have immuno-
modulatory activity [23]. MSCs inhibit T cell activation, dendritic cell
differentiation, and B cell proliferation and impair the cytolytic poten-
tial of natural killer cells in vitro [24]. Immunosuppression after MSC
infusion in vivo has also been documented in diverse animal models
of disease [25]. These effects are partially explained by the ability of
MSCs to secrete a vast array of soluble mediators, some of which
have immunomodulatory properties such as IL-10, prostaglandin E2,
or nitric oxide [21]. However, regulation of MSC lineage commitment
by immunomodulatorymolecules such as TLR ligands or cytokines has
not been well-deﬁned.
Here, we show that some TLR agonists are capable of utilizing in-
nate immune receptor TLRs to induce IL-6 expression in ASCs. Impor-
tantly, IL-6 signaling appears to be required to induce osterix, which
is an essential transcriptional factor for osteogenic differentiation.
Our data indicate a previously unappreciated molecular link between
the innate immune system and osteogenesis, and suggest that the
TLR/IL-6 signaling pathway may be useful for modulating osteogenic
differentiation of ASCs.
2. Materials and methods
2.1. Reagents
Synthetic triacylated lipoprotein Pam3CSK4, Salmonella Typhimurium
Flagellin, and R848 were purchased from InvivoGen (San Diego, CA).
Synthetic, double-stranded RNA analogue, polyinosinic:polycytidylic
acid (poly-IC), Escherichia coli 055:B5 LPS, and JSI-124 (Cucurbitacin I hy-
drate) were purchased from Sigma (St. Louis, MO). Human recombinant
IL-6 and sIL-6R were purchased from PeproTech (New Jersey, USA).
2.2. ASC isolation and culture
ASCs were obtained from 6- to 8-week-old male C57BL/6 mice
(The Jackson Laboratory) as described previously [26]. In brief, adi-
pose tissue dissected from a subcutaneous anterior abdominal wall
and cut into ﬁne pieces, was digested with 0.075% collagenase IA
(Sigma) for 1 h at 37 °C with vigorous shaking. The released cells
were centrifuged at 300 ×g for 10 min and the cell pellet, suspended
with PBS, was ﬁltered through a 100 μm cell strainer (BD Biosciences,
San Jose, CA) to remove tissue debris. Then, collagenase was removed
by dilution with PBS and centrifuged twice at 300 ×g for 10 min. The
cell pellet was suspended in 0.83% NH4Cl and incubated to remove
contaminating red blood cells. The residual cells were washed and
centrifuged twice with PBS and cultured in Dulbecco's modiﬁed
Eagle's medium (DMEM; HyClone, Logan, UT) supplemented with
10% FBS (HyClone), 100 units/ml penicillin, and 100 μg/ml strepto-
mycin (HyClone) in tissue cultured dishes at 37 °C in a 5% CO2 humid-
iﬁed incubator. After 4 h, non-adherent cells were removed by 2 to 3
washes with PBS; adherent cells were cultured further in complete
medium until the cells reached 80 to 90% conﬂuence. The adherent
cells were analyzed for immunophenotypic features. ASCs from pas-
sage 3 to passage 5 were used in all experiments described.
2.3. Induction of differentiation
The potential of the isolated cells to differentiate into osteogenic and
adipogenic lineages was examined as described previously [27]. For os-
teogenesis, cells were allowed to grow to 70% to 90% conﬂuence and
then cultured in osteogenic medium containing 10 mM β-glycerol
phosphate (Sigma), 50 μg/ml ascorbate-2-phosphate (Sigma), 10−7 M
dexamethasone (Sigma) and 25 ng/ml human recombinant bonemorphogenetic protein 2 (BMP-2, R&D Systems). The culture medium
was changed 3 times per week for 1 to 2 wk, respectively. The degree
of extracellular matrix calciﬁcation was estimated using Alizarin Red S
(2% ARS, pH 4; Alphachem, Middlesex, UK) staining and von Kossa
(1% silver nitrate solution; Sigma) staining. Alkaline phosphatase
(ALP) activity was detected by BCIP/NBT color development substrate
(Promega, Wisconsin, USA) according to the manufacturer's instruc-
tions. For adipogenesis, cells were allowed to grow to 70 to 90% conﬂu-
ence and then cultured in adipogenic medium containing 50 μg/ml
indomethacin (Sigma), 10−7 M dexamethasone (Sigma), 5 μg/ml insu-
lin (Sigma) and 10 μM rosiglitazone (Alexis). The culture medium was
changed 3 times per week for 1 to 2 wk and assessed by the use of an
oil red O staining as an indicator of intracellular lipid accumulation.
For oil red O quantiﬁcation, 4% IGEPAL CA 630 (Sigma) in isopropanol
was added to each well. Light absorbance by the extracted dye was
measured in 492 nm.2.4. Cytokines ELISA
ASCs were seeded in 96-well plates and, on the next day, were re-
placed to either control medium or medium containing various TLR
agonists. Conditioned medium were collected following treatment
for 6 h or 24 h and cytokine concentration was determined by
ELISA for IL-6, IL-1β, IL-10, IL-12(p40), and TNF (OptEIA kit; BD
Pharmingen, San Diego, CA) according to the manufacturer's instruc-
tions. Results were calculated from a standard curve.2.5. Evaluation of cell proliferation
To conﬁrm proliferative effects in TLR agonist treated ASCs, BrdU
cell proliferation kit (Roche Applied Science) was used. Cells were
seeded in a 96-well plate and incubated overnight to allow the cells
to adhere to the plate. The cells were treated with various TLR ago-
nists for 24 h, respectively. Each sample was assayed in triplicate.
After that, BrdU was added and the cells were reincubated for 4 h.
After removing the culture medium, cells were ﬁxed and the DNA de-
natured. Then, peroxidase-conjugated anti-BrdU was added to bind to
the BrdU. The immune complexes were detected by the 3,3′,5,5′
tetramethylbenzidine substrate reaction, and the resultant color was
read at 370 nm in a microplate spectrophotometer. The absorbance
values correlated directly to the amount of DNA synthesis and there-
by to the number of proliferating cells in culture.2.6. Reverse transcription PCR and real time PCR
Total RNAs were isolated from ASCs using TRIzol reagent
(Invitrogen) according to the manufacturer's instructions. After dena-
turation of total RNA at 70 °C for 10 min, ﬁrst-strand cDNA was syn-
thesized with oligo(dT) primers and MMLV-reverse transcriptase
(SolGent, Seoul, Korea). PCR ampliﬁcations were performed using
the speciﬁc primers. Primer sequences are shown in Supplementary
Table 1. PCR products were separated by agarose gel electrophoresis
and stained with ethidium bromide. The expression levels of each
sample were normalized against glyceraldehyde 3 phosphate dehy-
drogenase (GAPDH) mRNA expression. The relative mRNA levels of
osterix, ALP, and osteopontin were evaluated by real time PCR using
SYBR Green Master kit (Kapa Biosystems, Woburn, MA). Gene speciﬁc
primer sequences are shown in Supplementary Table 1. Reactions
were performed in triplicate on ABI PRISM 7300 unit (Applied
Biosystems). The relative expression levels were calculated using
the comparative CT method (ΔΔCT) and values were normalized to
actin level as an internal control gene. Melting curve analysis was in-
cluded to assure that only one PCR product was formed.
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Cells were lysed in cell lysis buffer containing 50 mM Tris–HCl
(pH 7.4), 150 mM NaCl, 0.5% sodium deoxycholate, 1% Nonidet P-40,
1 mM EDTA, 10% glycerol, 1 mM phenylmethylsulfonyl ﬂuoride,
1 μg/ml of leupeptin, aprotinin, and pepstatin A, 1 mM sodium
orthovanadate and 1 mMNaF for 20 min on ice. The lysates were cen-
trifuged at 14,000 ×g for 20 min at 4 °C. The supernatants were boiled
in SDS sample buffer containing 0.5 M β-mercaptoethanol. Protein
concentration was determined by the Bradford assay (Bio-Rad).
Equal amounts of proteins were separated by 10% SDS-PAGE and
electrotransferred to a nitrocellulose membrane (Millipore, Billerica,
MA, USA). The membrane was blocked in PBS containing 5% nonfat
drymilk for 1 h and then immunoblotted overnight at 4 °C on a shaker
with antibodies to phospho-Tyr705-STAT3, STAT3 (Cell Signaling Tech-
nology, Danvers, MA), osterix (Abcam, Cambridge, MA, USA), and
GAPDH (AbFrontier, Seoul, Korea) in Tris-buffered saline containing
0.05% Tween 20 (TBS-T)with 1% bovine serum albumin (BSA). Follow-
ing 2 washes in TBS-T, the membrane was incubated with either
horseradish peroxidase-conjugated anti-rabbit antibody or anti-
mouse antibody (Thermo Scientiﬁc) in TBS-T for 1 h at room temper-
ature. Proteins were detected using an ECL detection kit (Amersham
Biosciences, NJ, USA).
2.8. Immunoﬂuorescence assay
Serum-deprived ASCs grown on cover glass were treated with
either control medium (medium only) or containing 50 ng/ml IL-6
and 50 ng/ml sIL-6R for 1 h. Cells were washed in PBS and ﬁxed in
4% paraformaldehyde for 10 min and permeabilized with 0.1% Triton
X-100 for 20 min at RT. Cells were incubated in 5% BSA for 30 min at
RT and then incubated with anti-STAT3 (Cell Signaling Technology,
Danvers, MA) monoclonal antibody for 2 h at RT. After being washed
three times in PBS, cells were further incubated with Alexa Fluor
Red-conjugated goat anti-mouse IgG (Molecular Probes, Invitrogen,
CA) for 1 h at RT. Cells were washed again twice in PBS prior to
4′,6-diamidino-2-phenylindole (DAPI) staining andmounting. Images
were analyzed using the LSM 510 META laser confocal microscopy
system (Carl Zeiss Microimaging Inc., Thornwood, NY, USA).
2.9. Small interfering RNA (siRNA) transfection
Double-stranded, siRNAs (19-mer) targeting mouse STAT3 were
synthesized by Integrated DNA Technologies, Inc. (IDT; Coralville, IA).
The corresponding target mRNA sequences for the siRNAs were as
follows: si-STAT3, CAGCACAACCUUCGAAGAA; scrambled nontargeting
siRNA, ACGTGACACGTTCGGAGAA, as a negative control. ASCs were
transfected with the gene-speciﬁc siRNA at a concentration of 10 nM
using Lipofectamine™ RNAiMAX (Invitrogen) according to the
manufacturer's protocol.
2.10. Retroviral transduction
Retroviral vector encoding STAT3 was obtained from Addgene
(pMXs-STAT3C, Addgene plasmid 13373, Cambridge, MA, USA). The
plasmids were transfected into Plat-E cells, as described previously
[28], and the supernatant was collected 24 to 36 h after transfection.
The pMXs-puro vector and Plat-E cells were kindly provided by
T. Kitamura (University of Tokyo, Japan). The packaged retroviral par-
ticles in the supernatant were ﬁltered through 0.45 μm ﬁlters (BD
Biosciences), supplemented with polybrene (10 μg/ml; Sigma) then
used to infect ASCs that had been seeded 24 h before infection.
After 24 h, 1 μg/ml puromycin was added to the medium to select
for infected cells for 2 d. Puromycin-resistant cells were used in all
experiments described.2.11. Transfection and luciferase reporter assay
The pGL3-Osx reporter plasmid [29] containing mouse osterix
promoter from −2965 to +80 relative to the transcription start site
was kindly provided by Subburaman Mohan (Loma Linda University,
USA). ASCs were transfected with reporter constructs via electropora-
tion using the Neon Transfection System (Invitrogen, Carlsbad, CA)
according to the manufacturer's instructions. Brieﬂy, ASCs were treat-
ed with a single pulse of 1100 V for 30 ms, in a 100 μl electroporation
tip. On the next day, cells were cultured with or without 50 ng/ml
IL-6 and 50 ng/ml sIL-6R for 3 d. Luciferase activity was measured
by the luciferase assay system (Promega) and normalized to the ac-
tivity of the control (pRenilla). The data were obtained from 3 inde-
pendent transfections and presented as the -fold induction in
luciferase activity (mean ± S.D.) relative to the control.
2.12. Chromatin immunoprecipitation (ChIP) assay
ChIP assays were done using EZ-ChIP kit (Millipore, Bedford, MA)
as per manufacturer's instructions. In brief, 1 × 106 cells were treated
with either control medium (osteogenic differentiation medium) or
containing 50 ng/ml IL-6 and 50 ng/ml sIL-6R for 1 h. Then, formal-
dehyde was added at a ﬁnal concentration of 1% directly to cell cul-
ture medium for 10 min followed by a treatment with 125 mM
glycine. Cells were washed twice using cold PBS, resuspended in
500 μl of SDS lysis buffer containing protease inhibitors (1 mM
PMSF, 1 μg/ml leupeptin, aprotinin, and pepstatin A) and incubated
for 10 min on ice. Lysates were sonicated and cleared by centrifuga-
tion, and sonicated chromatin was diluted in ChIP dilution buffer
adding protease inhibitors as above. There was 1% of the diluted cell
supernatant with no primary antibody saved as total input chromatin.
The chromatin solution was precleared with the addition of salmon
sperm DNA/protein A agarose (50% slurry) for 1 h at 4 °C, then
precleared chromatin was incubated with STAT3 and mouse IgG for
control overnight at 4 °C with rotation. Immunoprecipitated com-
plexes were collected by adding salmon sperm DNA/protein A aga-
rose for 1 h at 4 °C with rotation. Following washing of the beads,
the histone complexes were eluted twice from the antibody. Eluates
were added 10 μl of 5 M NaCl and reversed the cross-links at 65 °C
for 4 h, and DNA was puriﬁed and recovered. PCR ampliﬁcations
were performed using with primers that detect sequences located in
the osterix promoter; 5′-TGACAGCCACCTGGTTCCAATACT-3′ (sense)
and 5′-GGGAGAAGAGTACCCACTTTCTTG-3′ (antisense). PCR products
were separated by agarose gel electrophoresis and stained with
ethidium bromide.
2.13. Statistical analysis
The data are presented as mean ± S.D. The Student's t-test was
used for statistical analysis. p b 0.05 was considered statistically
signiﬁcant.
3. Results
3.1. TLR agonists induce osteogenic differentiation of ASCs
To examine the role of TLRs in the osteogenic and adipogenic differ-
entiation of ASCs, we ﬁrst determined the TLR expression from total
RNA in murine ASCs. As a positive control, the murine monocyte/mac-
rophage RAW264.7 cell line expressed all TLRs tested (TLR1–TLR9). In
contrast, ASCs expressed a restricted TLR pattern featuredwith the tran-
scription of TLR1–TLR5 (Fig. 1A). Next, we examined the effect of TLR
agonists on osteogenic and adipogenic differentiation. As shown in Sup-
plementary Fig. 1, Pam3CSK4 (TLR1/2 agonist), poly-IC (TLR3 agonist),
and LPS (TLR4 agonist) reduced the intracellular lipid accumulation.
Interestingly, Pam3CSK4, poly-IC, LPS, and ﬂagellin (TLR5 agonist)
Fig. 2. ASCs secrete IL-6 in response to TLR agonists. ASCs were stimulated with or
without various concentrations of TLR agonists as indicated. Conditioned media were
collected from the culture plates after 6 or 24 h. The quantity of IL-6 was analyzed
by ELISA. Results represent the means ± S.D. of triplicate wells and are representative
of at least three independent experiments. *p b 0.01, **p b 0.001, signiﬁcantly different
from control.
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whereas R848 (TLR7/8 agonist) had no effect (Fig. 1B). Notably, ASCs
did not express TLR7/8. Moreover, TLR agonists had no effect on ASC
proliferation (Supplementary Fig. 2). These results suggest that TLR ag-
onists induced differentiation of ASCs into osteoblasts but not into
adipocytes.
3.2. TLR agonists induce IL-6
Because activating TLRs can inﬂuence cytokine secretion, we tested
the effect of TLR agonists on the production of cytokines by enzyme-
linked immunosorbent assay. Upon stimulation, the patterns of cytokine
expression and the magnitude of their expression varied depending on
the TLR agonist. Pam3CSK4, poly-IC, LPS, and ﬂagellin did not induce se-
cretion of pro-inﬂammatory cytokines including IL-1β or tumor necrosis
factor (TNF). LPS increased IL-10 and IL-12(p40), whereas Pam3CSK4,
poly-IC, and ﬂagellin did not (Supplementary Fig. 3). Most importantly,
Pam3CSK4, poly-IC, LPS, and ﬂagellin signiﬁcantly increased IL-6 secre-
tion depending on dose and time, but R848 and CpG (TLR9 agonist)
had less of an effect (Fig. 2).
3.3. IL-6 enhances osteogenic differentiation of ASCs
Considering TLR expression and IL-6 secretion in ASCs, it is possi-
ble that IL-6 might be involved in TLR-mediated osteogenic differen-
tiation. However, treatment of ASCs with IL-6 alone did not cause any
changes in Alizarin Red S staining (Supplementary Fig. 4A). Because
expression of the membrane-bound form of IL-6R was not detected
in ASCs by RT-PCR (Supplementary Fig. 4B), ASCs were incubated in
osteogenic medium containing IL-6 and sIL-6R for 2 wk. As shown
in Fig. 3A, ALP activity (upper) and Alizarin Red S (middle) and von
Kossa (lower) staining showed that exogenously adding IL-6/sIL-6R
stimulated osteogenic differentiation in a dose-dependent manner.Fig. 1. TLR agonists induce osteogenic differentiation of ASCs. (A) Total RNAs isolated from
lyzed by agarose gel electrophoresis. The RAW 264.7 cell line was used as positive contro
GAPDH was used as an internal loading control. (B) ASCs were cultured with osteogenic d
Osteogenic differentiation was detected after 2 wk by Alizarin Red S staining. Results are reIL-6/sIL-6R consistently increased mRNA levels of osterix, ALP, and
osteopontin (Fig. 3B). Interestingly, protein levels of the osterix tran-
scription factor essential for osteogenesis [30] were increased mark-
edly by IL-6/sIL-6R (Fig. 3C). These results suggest that the IL-6/
sIL-6R complex, but not IL-6 alone, plays a role in ASC osteogenesis.
3.4. TLR agonists activate STAT3 in ASCs
IL-6 induces nuclear translocation of STAT3 from the cytosol,
which results in STAT3-dependent gene expression. We investigatedASCs were ampliﬁed with TLR1–TLR9 speciﬁc primers. The ampliﬁed DNAs were ana-
l for PCR ampliﬁcation. Double distilled water (DDW) was used as a negative control.
ifferentiation medium containing various concentrations of TLR agonists as indicated.
presentative of at least three independent experiments.
Fig. 3. IL-6/sIL-6R enhances osteogenic differentiation of ASCs. (A) ASCs were incubated with osteogenic differentiation medium with or without the indicated concentrations of
IL-6 and sIL-6R. After 2 wk, ALP activity was determined by staining with NBT/BCIP staining (upper) and cellular mineralization was assessed by Alizarin Red S (middle) and
von Kossa (lower) staining. (B) ASCs were incubated with osteogenic differentiation medium containing IL-6 (100 ng/ml) and sIL-6R (100 ng/ml) for 2 wk. Total RNAs were iso-
lated from cultured ASCs to determine mRNA levels of osterix, ALP, and osteopontin by real time PCR analysis. Results represent means ± S.D. *p b 0.01, **p b 0.001, signiﬁcantly
different from IL-6 untreated control. (C) As in (A), except that total protein was isolated from cells to detect osterix expression by immunoblot analysis. GAPDH was used as the
internal loading control. Results are representative of at least three independent experiments.
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shown in Fig. 4A, IL-6/sIL-6R caused a rapid (within 5 min) and
long lasting increase in STAT3 phosphorylation levels. Furthermore,Fig. 4. IL-6/sIL-6R and TLR agonists activate STAT3 in ASCs. (A) ASCs were treated with or
immunoblotted with phospho-Tyr705-STAT3 antibody. Membranes were reblotted with GA
IL-6 (50 ng/ml) and sIL-6R (50 ng/ml) for 1 h to induce nuclear translocation of STAT3
Red-conjugated secondary antibody. DAPI was used to visualize the nuclei (original magniﬁ
(10 μg/ml), LPS (1 μg/ml), and R848 (1 μg/ml) for the indicated time periods. The levels of ph
immunoblot analysis. Results are representative of at least three independent experimentsSTAT3 translocated to the nucleus upon stimulation (Fig. 4B). To ex-
amine whether TLR agonists induce STAT3 phosphorylation, ASCs
were incubated with osteogenic medium in the presence of the TLRwithout IL-6 (50 ng/ml) and sIL-6R (50 ng/ml) for 5 min to 4 h, and cell lysates were
PDH antibody to ensure equal protein loading. (B) ASCs were treated with or without
. Then, the cells were ﬁxed and stained with anti-STAT3 antibody and Alexa Fluor
cation, ×40). (C) ASCs were stimulated with or without Pam3CSK4 (1 μg/ml), poly-IC
osphorylated STAT3 (Tyr705) and overall STAT3 were examined in whole cell lysates by
.
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Pam3CSK4, poly-IC, and LPS, but not R848, induced STAT3 phosphor-
ylation (Fig. 4C). These results suggest that some TLR agonists induce
IL-6 secretion by ASCs, and that IL-6 together with sIL-6R activates
STAT3.
3.5. STAT3 promotes osteogenic differentiation in ASCs
We analyzed the effect of STAT3 using siRNA-mediated gene si-
lencing to examine the role of STAT3 in osteogenic differentiation of
ASCs. Under STAT3 knockdown conditions (Fig. 5A), ASCs showed
slightly less ALP activity and calcium accumulation in the extracellu-
lar matrix as visualized by ALP (left) and Alizarin Red S (right) stain-
ing (Fig. 5B). STAT3 silencing also consistently decreased osterix, ALP,
and osteopontin expression in ASCs (Fig. 5C). We investigated the ef-
fects of STAT3 overexpression on osteogenesis to further conﬁrm the
role of STAT3. ASCs were transduced with a retroviral vector encoding
constitutively active STAT3 (STAT3C) [31]. Transduced ASCs in-
creased STAT3 expression (Fig. 5D), thereby resulting in signiﬁcantly
increased calcium accumulation as indicated by Alizarin Red S stain-
ing (Fig. 5E). Collectively, these data point to the importance of
STAT3 in osteogenesis.
3.6. STAT3 inhibitor blocks IL-6-induced osteogenic differentiation of
ASCs
We further investigated the effects of pharmacologically inhibiting
STAT3 on osteogenesis. Treatment of ASCs with 0.1 μM JSI-124 [32], a
STAT3 inhibitor, effectively blocked osteogenesis induced by IL-6/Fig. 5. STAT3 promotes osteogenic differentiation in ASCs. (A) ASCs were transiently transf
transfection, STAT3 expression was determined by immunoblot analysis. GAPDH was used a
ferentiation medium with or without IL-6 and sIL-6R for 2 wk. ALP activity was determined
(right panel). (C) As in (B), except that total RNAs were isolated from cells for real time PCR
against expression of actin mRNA. Experiments were repeated three times, and the results
scramble siRNA transfected control. (D) ASCs were infected with either retrovirus expressin
lysates were subjected to immunoblot analysis with anti-STAT3 antibody. (E) Cells infected
differentiation medium with or without IL-6 and sIL-6R for 2 wk. The extent of mineralized
dependent experiments.sIL-6R (Fig. 6A). JSI-124 markedly reduced the expression of osteo-
genic differentiation markers such as osterix, ALP, and osteopontin
(Fig. 6B). Furthermore, the inhibitor reduced STAT3 tyrosine phos-
phorylation and osterix protein levels, both of which were induced
by IL-6/sIL-6R (Fig. 6C).
3.7. STAT3 activates osterix promoter transcription
Based on our observations that IL-6/sIL-6R regulates osteogenesis
and also induces osterix transcription, we examined the involvement
of STAT3 in osterix induction. We analyzed the putative promoter re-
gion of mouse osterix using a program for predicting transcription
factor binding sites (Matlnspector software, http://www.genomatix.
de/). Indeed, two putative STAT3-binding sites [20] were present in
the 5′-ﬂanking region of osterix (Fig. 7A). The osterix promoter frag-
ment (−2965 to +80 relative to the transcription start site) linked to
a luciferase reporter construct conferred transcriptional activation
under IL-6/sIL-6R stimulation (Fig. 7B). Chromatin immunoprecipita-
tion (ChIP) assays indicated that the binding of STAT3 to the STAT3-
binding elements located−2593 and−2606 upstream in the osterix
promoter increased during osteogenesis induced by IL-6/sIL-6R
(Fig. 7C). Taken together, osterix is a direct transcriptional target of
STAT3 during IL-6/sIL-6R-induced osteogenesis of ASCs.
4. Discussion
ASCs represent a readily available and abundant supply of MSCs
that can be simply expanded to large numbers in vitro with less cell
heterogeneity [33,34]. Because ASCs differentiate into osteoblasts,ected with either 10 nM STAT3 siRNA or a nonrelevant siRNA (scrambled). After 48 h
s the loading control. (B) As in (A), except that cells were cultured with osteogenic dif-
by staining with NBT/BCIP (left panel) and mineralization was assessed by ARS staining
analysis. The mRNA expression levels of osterix, ALP, and osteopontin were normalized
represent average values from triplicate assays. *p b 0.001, signiﬁcantly different from
g GFP (pMXs) or constitutively active STAT3 (pMXs–STAT3C). After 48 h infection, cell
with pMXs or with pMXs–STAT3C expressing retrovirus were cultured in osteogenic
matrix was determined by ARS staining. Results are representative of at least three in-
Fig. 6. STAT3 inhibitor blocks IL-6/sIL-6R-induced osteogenic differentiation of ASCs. (A) ASCs were incubated with osteogenic differentiation medium containing IL-6 and sIL-6R as
indicated in the presence or absence of 0.1 μM JSI-124 for 2 wk. Following differentiation, ALP activity was determined by staining with NBT/BCIP (top panel) and mineralization
was assessed by ARS staining (bottom panel). (B) As in (A), except that total RNAs were subjected to real time PCR analysis to assess osterix, ALP, and osteopontin mRNA levels.
Experiments were repeated three times, and the results are mean values from triplicate assays. *p b 0.001, signiﬁcantly different from the inhibitor untreated control. (C) As in
Fig. 4A, except that cells were stimulated with IL-6/sIL-6R and JSI-124 as indicated for 5 min. Cell lysates were immunoblotted with phospho-Tyr705-STAT3, STAT3, and osterix an-
tibodies. GAPDH was used as the internal loading control. Results are representative of at least three independent experiments.
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[35], they are considered important for prospective cell-based thera-
py [36,37]. In this regard, the characterization of factors and mecha-
nisms that regulate ASC differentiation could allow us to manipulate
ASCs for therapeutic use. These studies demonstrate a novel role for
TLR signaling through IL-6/STAT3 during osteogenesis and further il-
lustrate the importance of this signaling pathway in the osteogenic
differentiation of ASCs.
TLR-mediated signals play prominent roles in initiating immune re-
sponses to infection [38]. In mammalian tissues, TLRs are highly
expressed by resident immune cells, including dendritic cells, tissue
macrophages, and mast cells and to a lesser degree by other cell types
including ﬁbroblasts, epithelial cells, and endothelial cells [39]. Upon
binding ligands, all known TLRs induce the production of inﬂammatory
cytokines including interferon (IFN)-α, IFN-β, IL-12(p40), TNF-α, IL-6,
and IL-1β, which attract innate immune cells and/or promote the initi-
ation and polarization of adaptive immune responses [40–42]. Besides
their role in innate and adaptive immune responses, a recent report
suggested that TLRs play an additional role as a sensor for endogenous
lipids, mostly through acting on adipose tissue [43,44]. TLRs appear to
have a role in generating non-infectious disease pathogenesis and
even in the maintenance of normal mammalian homeostasis [42,45].
In this context, our results extend TLR biology in mammalian systems
beyond its known immune functions and implicate TLR regulation in
the fate determination of ASCs.
Our ﬁrst important ﬁnding suggests functional links between TLR
expression, IL-6 secretion, and osteoblast differentiation in ASCs. ASCs
expressed several TLRs at themRNA level including TLR1–TLR5. Expres-
sion at the mRNA level does not necessarily mean that ASCs have func-
tional receptors. However, our ﬁndings indicate the functional status of
TLRs in ASCs. Pam3CSK4 (TLR1/2 agonist), poly-IC (TLR3 agonist), LPS
(TLR4 agonist), and ﬂagellin (TLR5 agonist) induced osteogenic differ-
entiation and IL-6 secretion, whereas R848 (TLR7/8 agonist) had noeffect. The lack of TLR7 and TLR8 expression may account for the
unresponsiveness to R848. Our data partially resemble those of
Pevsner-Fischer et al. [12], who found that humanMSCs expressedmul-
tiple TLRs, except TLR9, and that IL-6 is also secreted from MSCs incu-
bated with Pam3CSK4, peptidoglycan, LPS, and poly-IC, but not with
ssRNA40, imiquimod (R837), or CpG.
The second important ﬁnding in this study provides mechanistic in-
sights into the roles of IL-6 in ASC osteogenesis. IL-6 is a multifunctional
cytokine involved in the regulation of many systems. It plays a major
role regulating both inﬂammatory responses and hematopoiesis
[46–48]. We have shown that ASCs do not express membrane-bound
IL-6R at a detectable level and fail to respond to IL-6 alone, which was
consistent with the ﬁnding that MSCs lack IL-6R expression [49]. How-
ever, our results showed that a combination of IL-6 and sIL-6R enhanced
osteogenesis. It seems likely that ASCs that express no or little
membrane-bound IL-6R are able to respond to the IL-6/sIL-6R complex
as long as they express gp130. Notably, all cells in the body express
gp130 [17,50], and circulating levels of sIL-6R are maintained at sub-
stantially high levels in normal individuals (approximately 75 ng/ml)
[17,51]. Additionally, IL-6 concentrations produced by TLR agonists
from ASCs were 2–4 ng/ml, which were lower than the IL-6 concentra-
tion used in this study to stimulate ASCs in vitro. Plasma IL-6 levels are
barely detectable in healthy subjects (2–6 pg/ml) [51]; thus, the levels
of IL-6 induced by TLR agonists in ASCs are roughly 1000 times higher
than those of normal IL-6 plasma levels.
We found that TLR agonists such as Pam3CSK4, poly-IC, and LPS,
but not R848, as well as the exogenous addition of IL-6/sIL-6R to oste-
ogenic induction media induced STAT3 phosphorylation in ASCs. We
also observed that STAT3 phosphorylation showed a plateau of max-
imum stimulation within 5–30 min and decreased thereafter until
4 h. Given this time course, it is most likely that IL-6 secreted by
ASCs in response to TLR agonists activates STAT3 together with
sIL-6R, which has been observed in various body ﬂuids [52,53]. It is
Fig. 7. Transcriptional induction of osterix by STAT3 during osteogenesis. (A) Schematic
diagram of the murine osterix promoter sequences. Locations of the putative STAT3 bind-
ing sites at nucleotides−2593 and−2606 relative to the transcription site are indicated.
(B) ASCs were transiently transfected with reporter constructs containing mouse osterix
promoter from−2965 to +80 relative to the transcription start site. One day after, cells
were cultured in osteogenic differentiation medium with or without 50 ng/ml IL-6 and
50 ng/ml sIL-6R for 3 d followed by luciferase assay. Data were obtained from three inde-
pendent transfections and presented as the fold induction over the activity of pGL3-basic
without IL-6/sIL-6R treatment (mean ± S.D.). *p b 0.01, signiﬁcantly different from IL-6/
sIL-6R untreated control. (C) ChIP analysis of STAT3 binding to the osterix promoter. ASCs
were treatedwith orwithout 50 ng/ml IL-6 and 50 ng/ml sIL-6R for 1 h to induce nuclear
STAT3 translocation. ChIP assays were performed on cell lysates by using an STAT3 anti-
body followed by PCR analysis. Input corresponded to PCR containing 1% of the total
amount of chromatin used in the immunoprecipitation reactions. Results are representa-
tive of three independent immunoprecipitations.
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known to promote osteogenic differentiation. In support of this hy-
pothesis, we clearly demonstrated that IL-6/sIL-6R-induced STAT3
phosphorylation is critical for the induction of osterix, which is an es-
sential early stage transcription factor for osteoblast differentiation
[30]. Indeed, the ChIP assays showed that IL-6/sIL-6R induced binding
of STAT3 to sequences in the osterix promoter within ASCs.
IL-6 is widely recognized as a potent stimulator of osteoclast-
driven bone resorption in the context of chronic inﬂammation and es-
trogen deﬁciency [54]. Estrogen depletion causes signiﬁcant bone loss
together with increased bone turnover rates in wild type animals, but
ovariectomy fails to induce any changes in either bone mass or bone
remodeling rates in the IL-6-deﬁcient mice [55], suggesting that IL-6
may play a role in menopausal osteoporosis. Given the key role of
IL-6 in inﬂammatory diseases such as rheumatoid arthritis, it is im-
portant to note that therapeutic blockade of IL-6 has begun to offer
therapeutic strategies for treating rheumatoid arthritis. For example,
Tocilizumab, a humanized monoclonal antibody against the IL-6R, is
used for the treatment of moderate to severe rheumatoid arthritis
in adults [56].
The origin of MSCs or ASCs may determine their fate and function-
al characteristics [57]. Furthermore, the exact functions of MSCs or
ASCs within tissues remain largely unknown, but they appear to per-
form distinct roles in speciﬁc tissues where they reside. In thiscontext, MSCs or ASCs may differentiate into specialized cells upon
receiving TLR signals during tissue inﬂammation or injury and play
a pivotal role in tissue repair and/or in control of inﬂammation.
In summary, although some TLRs play a role in MSC functions, the
molecular mechanisms through which TLR signals are transduced to
produce cytokines, which then promotes osteogenic differentiation,
have remained obscure. We have shown here that some TLR agonists
are capable of utilizing the innate immune TLR receptors to induce
IL-6 expression in ASCs. Moreover, IL-6/STAT3 signaling appears to
be required to induce the expression of osterix, which is an essential
transcription factor for osteogenic differentiation.Acknowledgements
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